Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
January 16, 2019
Nature Communications

OHSU CTD2 scientists identify distinct patterns of mutation dynamics during FLT3 inhibitor, crenolanib treatment in acute myeloid leukemia. This study indicates comprehensive sequencing should be carried before and during the treatment to identify combinatorial agents and prevent drug resistance.

CTD²
January 10, 2019
Cell

Study identifies networks of DNA damage-up proteins that may predict tumorigenic functions of cancer-promoting proteins.

CTD²
January 07, 2019
PLoS One

CTD2 researchers developed phospho-proteomic specific algorithm, pARACNe, which measures phospho-state dependencies between tyrosine kinases and their candidate substrates from large-scale LC-MS/MS phosphoproteomic profiles.

CGCI
January 07, 2019
Blood

Scientists from BLGSP demonstrated that tumor EBV status defines a specific BL phenotype irrespective of geographic origin with particular molecular properties and distinct pathogenic mechanisms. EBV-positive BL genomes feature fewer driver mutations despite their greater mutational load.

CTD²
January 04, 2019
Experimental Hematology

Review on using human pluripotent stem cells derived natural killer cells and macrophages as a novel cell-based approach for cancer immunotherapy.

CTD²
December 27, 2018
Blood

Concurrent measurement of single cell expression in tumor cells and tumor-infiltrating lymphocytes revealed novel biological insights of the tumor microenvironment; provides basis for developing novel therapeutic targets in lymphoma.

CTD²
December 26, 2018
Cell Systems

Bioinformatic approach, Similarity Weighted Nonnegative Embedding (SWNE), enables visualization of single-cell gene expression data into biologically relevant factors.

CTD²
December 24, 2018
OncoImmunology

UCSD study suggests that combination of APOBEC-related mutagenesis and tumor mutation burden may be used as a biomarker of response to immunotherapy.

CTD²
December 21, 2018
Nature Communications

Researchers at DFCI analyzed genome-scale loss-of-function datasets and identified adenosine deaminase acting on RNA as a gene dependency in subsets of lung cancer.

CTD²
December 17, 2018
Cold Spring Harbor Molecular Case Studies

Scientists report that two myeloid leukemia cases with FMS-like tyrosine kinase (FLT3) fusions demonstrate mixed features of myelodysplastic and myeloproliferative syndromes; showed sensitivity to FLT3 inhibitors in ex vivo drug screening assays.

Pages

CSVXML